Coherus BioSciences (CHRS) Tops Q2 EPS by 11c ; Offers Guidance
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $1.33 -0.75%
EPS Growth %: +39.4%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
ANAB, ANIX, MNY, More
EPS Growth %: +39.4%
Financial Fact:
Depreciation and amortization: 14.21M
Today's EPS Names:
ANAB, ANIX, MNY, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q2 EPS of ($0.14), $0.11 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $65 million versus the consensus estimate of $56.41 million.
GUIDANCE:
Coherus BioSciences sees FY2024 revenue of $250-265 million, versus the consensus of $259.3 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Corning (GLW) files for up to $2B offering of common shares
- Trilogy Metals closes $35.6M investment from U.S. Department of War
- Northrop Grumman wins two U.S. defense contracts worth $38.7m
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
